» Authors » Stefan B Eichmuller

Stefan B Eichmuller

Explore the profile of Stefan B Eichmuller including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 65
Citations 1335
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Roberti M, Charoentong P, Lyu Y, Meyer M, Eichmuller S, Schmidt P, et al.
Oncoimmunology . 2025 Feb; 14(1):2457793. PMID: 39902862
T cells that recognize tumor-specific mutations are crucial for cancer immunosurveillance and in adoptive transfer of TILs or transgenic-TCR T cell products. However, their challenging identification and isolation limits their...
2.
Laurent P, Andre F, Bobard A, Deandreis D, Demaria S, Depil S, et al.
Oncoimmunology . 2024 Dec; 14(1):2432726. PMID: 39696783
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring...
3.
Meyer M, Parpoulas C, Barthelemy T, Becker J, Charoentong P, Lyu Y, et al.
Front Immunol . 2024 Jan; 14:1294565. PMID: 38239352
Peptide-loaded MHC class I (pMHC-I) multimers have revolutionized our capabilities to monitor disease-associated T cell responses with high sensitivity and specificity. To improve the discovery of T cell receptors (TCR)...
4.
Kordass T, Chao T, Osen W, Eichmuller S
Front Immunol . 2023 Jul; 14:1199374. PMID: 37409119
Introduction: The expression of immune checkpoint molecules (ICMs) by cancer cells is known to counteract tumor-reactive immune responses, thereby promoting tumor immune escape. For example, upregulated expression of ecto-5'-nucleotidase (NT5E),...
5.
Pane A, Kordass T, Hotz-Wagenblatt A, Dickes E, Kopp-Schneider A, Will R, et al.
Clin Transl Med . 2023 Jan; 13(2):e1186. PMID: 36718025
Background: The regulatory functions of microRNAs (miRNAs) in anti-tumour immunity have been mainly described in immune effector cells. Since little is known about miRNA effects on the susceptibility of target...
6.
Kehl N, Kilian M, Michel J, Wagner T, Uhrig S, Brobeil A, et al.
J Immunother Cancer . 2022 Oct; 10(10). PMID: 36252999
Multiple myeloma (MM) is a hematological malignancy originating from malignant and clonally expanding plasma cells. MM can be molecularly stratified, and its clonal evolution deciphered based on the Ig heavy...
7.
Hartmann L, Osen W, Eichmuller O, Kordass T, Furkel J, Dickes E, et al.
Cancer Lett . 2022 Oct; 550:215928. PMID: 36183858
Radiotherapy can act as an in situ vaccine, activating preventive tumor-specific immune responses in patients. Although carbon ion radiotherapy has superior biophysical properties over conventional photon irradiation, the immunological effects...
8.
Chao T, Kordass T, Osen W, Eichmuller S
Mol Cell Biochem . 2022 Jul; 478(2):305-315. PMID: 35779228
The transcription factor SOX9 represents an important mediator of breast cancer progression. miRNAs are small non-coding RNAs inhibiting translation of target genes upon interaction with the 3'-UTR region of respective...
9.
Hernandez-Malmierca P, Vonficht D, Schnell A, Uckelmann H, Bollhagen A, Mahmoud M, et al.
Cell Stem Cell . 2022 May; 29(5):760-775.e10. PMID: 35523139
Hematopoietic stem and progenitor cells (HSPCs) are responsible for the production of blood and immune cells. Throughout life, HSPCs acquire oncogenic aberrations that can cause hematological cancers. Although molecular programs...
10.
Kilian M, Friedrich M, Sanghvi K, Green E, Pusch S, Kawauchi D, et al.
Clin Cancer Res . 2021 Nov; 28(2):378-389. PMID: 34782365
Purpose: Gliomas are intrinsic brain tumors with a high degree of constitutive and acquired resistance to standard therapeutic modalities such as radiotherapy and alkylating chemotherapy. Glioma subtypes are recognized by...